Sales growth accelerated further in Q3 as immunoassays returned into the black after five consecutive quarters of negative lfl growth. Sustained demand for FilmArray and a pick-up in sales in industrial applications bolstered growth further. Despite this sales beat, management has turned cautious with its FY19 sales outlook – tough comps and heightening competition signals sales deceleration in Q4. With top-line growth momentum fading away, bioMerieux could now take the inorganic route ....